Journal of Clinical Oncology
Articles in this Issue
Survival trends and disparities in indolent and aggressive non-Hodgkin lymphoma.
e23109 Background: Overall survival (OS) in non-Hodgkin lymphoma (NHL) has improved with therapeutic advances. Whether the...
Efficacy, tolerability, and outcomes of generic palbociclib in metastatic HR-positive, HER2-negative breast cancer: An ambispective study from a tertiary cancer center in South India.
e13034 Background: CDK4/6 inhibitors have transformed outcomes in hormone receptor (HR)-positive, HER2-negative metastatic...
Evaluation of concomitant medications in advanced prostate cancer patients receiving apalutamide: TITAN and SPARTAN post-hoc analysis.
5087 Background: Apalutamide (APA) is an androgen receptor pathway inhibitor (ARPI) approved for use with androgen-depriva...
Prevalence of germline cancer predisposition pathogenic variants in cancer cohorts.
e22667 Background: Clinical practice guidelines recommend germline genetic testing for a broadening scope of incident adul...
Association between specific cancer types and polyarteritis nodosa among hospitalized patients in the United States.
e18631 Background: Since immunization programs drastically reduced Hepatitis-B associated polyarteritis nodosa (PAN), the...
Impact of pain on functional status, quality of life, and cognition in older adults with prostate cancer.
e23084 Background: Pain is a common symptom in patients with cancer that can be compounded by aging. Studies of its multid...
Trends in mortality due to heart failure and malignant neoplasms among adult patients in the United States: A 25-year nationwide retrospective analysis with 12-year future projections.
e24002 Background: Malignant neoplasms and heart failure (HF) are major contributors to morbidity and mortality in older a...
Post-prophylaxis CMV in the letermovir era: Incidence, risk factors, and outcomes following HCT.
6561 Background: Cytomegalovirus (CMV) is a major infectious complication after allogeneic hematopoietic cell transplantat...
Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.
2569 Background: Immune activation is important for survival in cancer. Eftilagimod alfa (E), an antigen-presenting cell (...
Trilaciclib for myeloprotection in adjuvant and first-line chemotherapy for advanced gastric/gastroesophageal junction adenocarcinoma: A multicohort study.
12152 Background: Chemotherapy-induced myelosuppression (CIM) has become one of the important limiting factors in the trea...
Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.
TPS9608 Background: Uveal melanoma (UM) is the most common intraocular malignancy and has high risk of metastatic progress...
Phase II basket trial of brigatinib for <i>ALK</i> fusion–positive solid tumors: ALLBREAK trial (WJOG15221M).
3105 Background: ALK fusions occur in approximately 0.2% of solid tumors other than non-small cell lun...
Treatment-related hypomagnesemia and pertuzumab discontinuation in HER2-positive breast cancer: A decade of Appalachian data.
e12677 Background: Breast cancer remains the most frequently diagnosed cancer among women. Intensive chemotherapy for earl...
Risk of venous thromboembolism in resectable non-small cell lung cancer treated with neoadjuvant and adjuvant immunotherapy: A self-controlled case series.
e20100 Background: In October 2021, atezolizumab was approved for adjuvant treatment of non–small cell lung cancer (NSCLC)...
Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).
e19504 Background: Initiation of bsAbs requires SUD with close monitoring, typically in IP settings, to mitigate early tox...
Profiling patients with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.
8612 Background: Tepotinib is a highly selective MET inhibitor with clinical activity in patients with...
Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in <i>K-Ras</i> –mutated pancreatic cancers.
e16427 Background: AKTX-101 is a TROP2 ADC containing the spliceosome modulator payload, PH1(1). PH1 can target oncogenic...
Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.
3143 Background: GLP-1 receptor agonists (GLP-1RAs) are pleiotropic medications, initially developed for diabetes, yet wit...
A silent but rising threat: Increasing small intestinal cancer mortality among older adults in the United States.
e16482 Background: Small intestinal cancer is a rare but increasingly diagnosed malignancy that presents unique management...
Second-line TKI therapy following first-line immune checkpoint inhibitor combinations in metastatic RCC: A systematic review and meta-analysis of safety outcomes.
e16561 Background: Sequential tyrosine kinase inhibitor (TKI) therapy following immune checkpoint inhibitor (ICI)-based fi...
Sequencing of PARP inhibitors and taxane chemotherapy in HRR-altered metastatic castration-resistant prostate cancer: A real-world VA analysis.
5072 Background: Taxane-based chemotherapy (taxane) and poly(ADP-ribose) polymerase inhibitors (PARPi) are established lif...
Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma.
9533 Background: ctDNA is becoming a useful biomarker for ICI treatment response assessment in advanced melanoma. RT is ca...
GLIX1: A first-in-class oral molecule targeting the DNA damage response by restoring TET2 activity.
e14072 Background: The Ten-Eleven Translocation methylcytosine dioxygenase 2 (TET2) initiates the DNA demethylation by oxi...
Dual pathology, amplified risk? Understanding outcomes in TLS with concurrent heart failure.
e18618 Background: Tumor lysis syndrome (TLS) is a life-threatening oncological emergency that is associated with end-orga...
Spatial mapping of fibroblast subtypes in primary colorectal cancer.
e15665 Background: Colorectal cancer (CRC) is the third leading cause of cancer related death. CRC arises from colon stem...